SZSE Ticker: 002773

Chengdu Kanghong Pharmaceutical Group Co., Ltd

成都康弘药业集团股份有限公司

康弘药业

KHPG

Listing Date: 2015-06-26

Board: SME

Industry Classification: Manufacturing

Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated

Post date May 16, 2022 — 08:44 Post Lock

Survive the broken arm! In the cold winter, another star drug was forced to terminate the clinical trial enterprise, and how did the capital start again jqknews

Post date May 15, 2022 — 21:44 Post Lock

Kaiyuan Securities: Continue to be optimistic about investment opportunities in the new crown testing, consumer medical and new crown drug industry chains

Post date May 10, 2022 — 10:07 Post Lock

Announcement at noon on May 9: A wholly-owned subsidiary of Poinsettia obtained the registration certificate of venlafaxine hydrochloride sustained-release capsules

Post date May 9, 2022 — 12:09 Post Lock

Good news express: The two offices issued the "Opinions on Promoting Urbanization Construction with County Towns as an Important Carrier", the government promoted the vigorous development of green buildings, and Tianbang's sales of commercial pigs in April increased by 34.56% month-on-month

Post date May 9, 2022 — 09:00 Post Lock

Kanghong Pharmaceutical's new indication of Conbercept ophthalmic injection approved_Shenzhen Hotline

Post date May 7, 2022 — 20:07 Post Lock

Kanghong Pharmaceutical achieves a net profit of 421 million yuan in 2021, and the business performance of proprietary Chinese medicines and biological products is outstanding

Post date May 4, 2022 — 23:29 Post Lock

Kanghong Pharmaceutical: Net profit in the first quarter of 2022 is about 297 million yuan, an increase of 27.22% year-on-year

Post date April 30, 2022 — 16:20 Post Lock

Kanghong Pharmaceutical: Net profit in the first quarter of 2022 is about 297 million yuan, a year-on-year increase of 27.22% – yqqlm

Post date April 30, 2022 — 16:18 Post Lock

Kanghong Pharmaceutical: Net profit in 2021 is about 421 million yuan

Post date April 30, 2022 — 16:15 Post Lock

Kanghong Pharmaceutical: Received the Drug Clinical Trial Approval Notice for Obeticholic Acid Tablets

Post date April 24, 2022 — 22:44 Post Lock

Announcement of Chengdu Kanghong Pharmaceutical Group Co., Ltd. on the use of its own funds to purchase wealth management products

Post date April 16, 2022 — 07:15 Post Lock

The utilization rate of traditional Chinese medicine among those with positive infection in Shanghai exceeds 98%.

Post date April 6, 2022 — 19:31 Post Lock

There are many well-known companies and well-known varieties of 77 drug applications withdrawn from the Internet

Post date April 3, 2022 — 07:41 Post Lock